## Abstract The effect on bladder function of protectomy for colitis or Crohn's disease was studied by means of a questionnaire and by pressure/flow cystometry. Thirty-seven patients who had undergone protectomy for inflammatory bowel disease were compared with 34 control patients who had undergone
Systematic review of postoperative complications in patients with inflammatory bowel disease treated with immunomodulators
β Scribed by V. Subramanian; R. C. G. Pollok; J.-Y. Kang; D. Kumar
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 109 KB
- Volume
- 93
- Category
- Article
- ISSN
- 0007-1323
- DOI
- 10.1002/bjs.5375
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Background
This systematic review examined the use of immunomodulators and the risk of postoperative complications after abdominal surgery in patients with inflammatory bowel disease.
Methods
Electronic databases (PubMed, Embase, Ingenta, Zetoc and Ovid) were searched and the reference lists in all articles identified were hand-searched for further relevant papers. Studies were included if they evaluated postoperative complications and defined exposure to individual immunomodulators.
Results
All 11 studies that met the inclusion criteria were observational studies; two were reported only in abstract form. Five studies reported risks associated with azathioprine, five reported risks associated with cyclosporin and three reported risks associated with infliximab. None showed an increased risk of either total or infectious complications associated with immunomodulator use. However, subgroup analysis in one study, published as an abstract, suggested increased rates of anastomotic complications and reoperation associated with azathioprine.
Conclusion
Available evidence does not suggest an increased rate of postoperative complications associated with immunomodulator use.
π SIMILAR VOLUMES
## Abstract ## Objective Ankylosing spondylitis (AS) and inflammatory bowel disease (IBD) are clinically and pathologically linked. Antiβtumor necrosis factor (antiβTNF) agents are efficacious in treating AS, but not all are equally effective in treating IBD (Crohn's disease [CD] and ulcerative co